SCHEMBL6785403

SCHEMBL6785403

COC(=O)c1ccccc1NC(=O)/C=C(/C)c1ccc(Cl)c(Br)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 3/20 0.53
LMNA P02545 4/20 0.48
HPGD P15428 4/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
HTT P42858 1/20 0.48
MAPK1 P28482 1/20 0.45
TSHR P16473 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C19 P33261 1/20 0.44
KMT2A Q03164 3/20 0.44
KDM4E B2RXH2 4/20 0.44
HSD17B10 Q99714 2/20 0.44
ALDH1A1 P00352 6/20 0.43
GAA P10253 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MAPT P10636 2/20 0.43
RAB9A P51151 2/20 0.43
LTB4R Q15722 1/20 0.43
MEN1 O00255 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6786460 0.91 TERT (0.53) TERTLMNAHPGDSMN1; SMN2HTT
SCHEMBL6784249 0.90 TERT (0.56) TERTLMNAHPGDSMN1; SMN2HTT
SCHEMBL6785189 0.89 TERT (0.67) TERTLMNAHPGDSMN1; SMN2HTT
SCHEMBL6786403 0.85 KDM4E (0.50) LMNAHPGDSMN1; SMN2HTTMAPK1
SCHEMBL6785118 0.82 LMNA (0.54) TERTLMNAHPGDSMN1; SMN2HTT
SCHEMBL6784219 0.81 TERT (0.78) TERTLMNAHPGDSMN1; SMN2HTT
SCHEMBL6785704 0.81 TERT (0.56) TERTLMNAHPGDSMN1; SMN2HTT
SCHEMBL4025243 0.80 TERT (0.67) TERTLMNAHPGDSMN1; SMN2HTT
SCHEMBL7241600 0.79 TERT (0.57) TERTLMNAHPGDSMN1; SMN2HTT
SCHEMBL6782877 0.79 HPGD (0.54) TERTLMNAHPGDSMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885LMNA 169/4885HPGD 1051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.